Wetherby Asset Management Inc. increased its stake in Sanofi (NYSE:SNY) by 3.9% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 30,035 shares of the company’s stock after buying an additional 1,130 shares during the period. Wetherby Asset Management Inc.’s holdings in Sanofi were worth $1,439,000 as of its most recent filing with the SEC.

Several other hedge funds also recently added to or reduced their stakes in the company. Guggenheim Capital LLC increased its stake in Sanofi by 1.5% in the fourth quarter. Guggenheim Capital LLC now owns 21,558 shares of the company’s stock valued at $872,000 after buying an additional 311 shares during the period. Goodwin Daniel L bought a new stake in Sanofi during the second quarter valued at about $239,000. Cullinan Associates Inc. increased its stake in Sanofi by 5.5% in the first quarter. Cullinan Associates Inc. now owns 64,000 shares of the company’s stock valued at $2,896,000 after buying an additional 3,340 shares during the period. Wellington Management Group LLP bought a new stake in Sanofi during the first quarter valued at about $2,252,000. Finally, Stifel Financial Corp increased its stake in Sanofi by 8.6% in the first quarter. Stifel Financial Corp now owns 317,185 shares of the company’s stock valued at $14,362,000 after buying an additional 25,009 shares during the period. Institutional investors own 9.96% of the company’s stock.

Sanofi (NYSE:SNY) opened at 47.75 on Thursday. Sanofi has a 52-week low of $36.81 and a 52-week high of $50.24. The company’s 50 day moving average price is $48.08 and its 200 day moving average price is $46.05. The firm has a market cap of $119.92 billion, a PE ratio of 11.28 and a beta of 0.88.

Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The firm had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi’s revenue was down 2.3% on a year-over-year basis. Analysts predict that Sanofi will post $3.26 earnings per share for the current fiscal year.

WARNING: “Sanofi (SNY) Stake Boosted by Wetherby Asset Management Inc.” was posted by Watch List News and is the property of of Watch List News. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.watchlistnews.com/sanofi-sny-stake-boosted-by-wetherby-asset-management-inc/1470106.html.

Several analysts have recently issued reports on SNY shares. Zacks Investment Research downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Tuesday, April 25th. BidaskClub upgraded Sanofi from a “hold” rating to a “buy” rating in a research note on Friday, June 23rd. J P Morgan Chase & Co reiterated a “neutral” rating on shares of Sanofi in a research note on Thursday, April 20th. Cowen and Company reiterated a “market perform” rating and set a $52.00 price target (up previously from $46.00) on shares of Sanofi in a research note on Tuesday, August 1st. Finally, Berenberg Bank downgraded Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $63.75.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Want to see what other hedge funds are holding SNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sanofi (NYSE:SNY).

Institutional Ownership by Quarter for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with Analyst Ratings Network's FREE daily email newsletter.